Immunohistochemical Detection of VEGF in the Bone Marrow of Patients with Chronic Myeloid Leukemia and Correlation with the Phase of Disease

American Journal of Clinical Pathology

Volumn 121, Issue 4, 2004, Pages 473-481

  Krauth, Maria Theresa ^a   Simonitsch, Ingrid ^a   Aichberger, Karl J ^a   Mayerhofer, Matthias ^a   Sperr, Wolfgang R ^a   Sillaber, Christian ^a   Schneeweiss, Bruno ^b   Mann, Georg ^c   Gadner, Helmut ^c   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Landes Krankenhaus Kirchdorf   (Austria)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Angiogenesis; Chronic myeloid leukemia; CML; Leukemia; Vascular endothelial growth factor; VEGF

Indexed keywords

ALPHA INTERFERON; HYDROXYUREA; IMATINIB; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW; BONE MARROW CELL; CELL TYPE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ERYTHROID CELL; FEMALE; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL; MALE; MEGAKARYOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; STEM CELL;

EID: 12144287119     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/3JLTFNNEDQHB4A0P     Document Type: Article

References (32)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-3356.
2. Faderl S, Talpaz M, Estrov Z, et al. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999;131:207-219.
3. Nowell PC, Hungerford DA. Chromosome studies in human leukemia, II: chronic granulocytic leukemia. J Natl Cancer Inst. 1961;27:1013-1035.
4. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
5. Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986;233:212-214.
6. Sattler M, Griffin JD. Mechanisms of transformation by the bcr/abl oncogene. Int J Hematol. 2001;73:278-291.
7. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
8. Vardiman JW, Pierre R, Thiele J, et al. Chronic myelogenous leukaemia. In: Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:20-26. World Health Organization Classification of Tumours.
9. Khalidi HS, Brynes RK, Medeiros LJ, et al. The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in "lymphoid" blasts and a comparison of morphologic, immunophenotypic, and molecular findings. Mod Pathol. 1998;11:1211-1221.
10. Kantarjian H, O'Brien S, Cortes J, et al. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer. 2003;98:81-85.
11. Shet AS, Jahagirdar BN, Verfaillie CM. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia. 2002;16:1402-1411.
12. Ohmine K, Ota J, Ueda M, et al. Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. Oncogene. 2001;20:8249-8257.
13. Bruchova H, Borovanova T, Klamova H, et al. Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea. Leuk Lymphoma. 2002;43:1289-1295.
14. Jiang X, Lopez A, Holyoake T, et al. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 1999;96:12804-12809.
15. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76-94.
16. Schwartz J, Pinilla-Ibarz J, Yuan RR, et al. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia. Semin Hematol. 2003;40:87-96.
17. Musolino C, Calabro' L, Bellomo G, et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol. 2002;69:159-163.
18. Sillaber C, Mayerhofer M, Valent P. Angiogenic factors in chronic myeloid leukemia: role of the bcr/abl oncogene, biochemical mechanisms, and potential clinical implications. Eur J Clin Invest. In press.
19. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-2245.
20. Lundberg LG, Lerner R, Sundelin P, et al. Bone marrow in polycythemia vera, chronic myeloid leukemia, and myelofibrosis has increased vascularity. Am J Pathol. 2000;157:15-19.
21. Fielder W, Graeven U, Ergun S, et al. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia. 1997;11:1234-1237.
22. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001;97:1427-1434.
23. Mayerhofer M, Valent P, Sperr WR, et al. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, HIF-1α, through a pathway involving PI3-kinase and the mammalian target of rapamycin (mTOR). Blood. 2002;100:3767-3775.
24. Janowska-Wieczorek A, Majka M, Marquez-Curtis L, et al. bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia. 2002;16:1160-1166.
25. Ebos JM, Tran J, Master Z, et al. Imatinib mesylate (STI-571) reduces bcr-abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res. 2002;1:89-95.
26. Verstovsek S, Kantarjian H, Manshouri T, et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 2002;99:2265-2267.
27. Wimazal F, Jordan J-H, Sperr WR, et al. Increased angiogenesis in the bone marrow of patients with systemic mastocytosis. Am J Pathol. 2002;160:1639-1645.
28. Ghannadan M, Wimazal F, Simonitsch I, et al. Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia: correlation between VEGF expression and the FAB category. Am J Clin Pathol. 2003;119:663-671.
29. Chomczynski P. One-hour downward alkaline capillary transfer for blotting DNA and RNA. Anal Biochem. 1992;201:134-139.
30. Milanini J, Vinals F, Pouyssegur J, et al. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem. 1998;273:18165-18172.
31. Hubmann R, Schwarzmeier JD, Shehata M, et al. Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood. 2002;99:3742-3747.
32. Padro T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGVR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia. 2002;16:1302-1310.